Page 172 - Neuropsychiatric.indd

87. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal 98. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al.
anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll

Heart Association. Circulation. 2007;115(12):1634-42. Cardiol. 2020;75(1):76-92.
88. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti- 99. Cosyns B, Droogmans S, Rosenhek R, Lancellotti P. Drug-induced valvular heart disease.
inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Heart. 2013;99(1):7-12.
Ther. 2017;42(1):27-38. 100. Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc

89. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse Dis. 2013;106(5):333-9.
events in the mortality difference between first and second-generation antipsychotics in 101. Daskalov IR, Valova-Ilieva. Management of acute pericarditis: treatment and follow-up.
older adults: systematic review and meta-synthesis. PLoS One. 2014;9(8):e105376. [accessed 29 November 2020]. Available from: https://www.escardio.org/Journals/E-

90. Imitrex (sumatriptan). Product information. [accessed 29 November 2020]. Available from: Journal-of-Cardiology-Practice/Volume-15/Management-of-acute-pericarditis-treatment-
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020132s024s026lbl.pdf and-follow-up
91. Cafergot (ergotamine and caffeine). Product information. [accessed 29 November 2020]. 102. Martínez Quintana E, Llorens León R, Redondo Martínez E, Nieto Lago V, Jiménez
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label /2002/ 9000s22s Cabrera F, Gross Kastanovitz E. Valvular heart disease associated with ergotamine. Rev
23lbl.pdf Esp Cardiol. 2005;58(1):97-9

92. Viagra (sildenafil). Product information. [accessed 29 November 2020]. Available from: 103. Forbat LN, Hancock BW, Gershlick AH. Methotrexate-induced pericarditis and pericardial
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s042lbl.pdf effusion; first reported case. Postgrad Med J. 1995;71(834):244-5.
93. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014

ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and
management of patients with stable ischemic heart disease: a report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines, and
the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses

Association, Society for Cardiovascular Angiography and Interventions, and Society of
Thoracic Surgeons. J Am Coll Cardiol. 2014;64(18):1929-49.
94. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014
AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary

Syndromes: a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-228.
95. Yildirim U, Gulel O, Soylu K, Yuksel S, Sahin M. Steroid-induced recurrent myocardial
ischemia. Rev Port Cardiol. 2014;33(7-8):473.e1-4.

96. Spinler SA, Silvestry FE. Chapter 29 Valvular and pericardial heart disease. In: Tisdale JE et
al., eds. Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. United
States: American Society of Health-System Pharmacists, Inc., 2018.
97. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA

Guideline for the management of patients with valvular heart disease: executive summary:
A report of the American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71.

150 151
151